Evidence map›Paper›PMID 40029670›Full record

ArticleMolecular pharmaceutics2025

Investigating the Interaction between Excipients and Monoclonal Antibodies PGT121 and N49P9.6-FR-LS: A Comprehensive Analysis.

Xun Li, Asuka A Orr, Mohammad M Sajadi, Anthony L DeVico, Daniel J Deredge, Alexander D MacKerell, Stephen W Hoag

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xun LiSchool of Pharmacy, University of Maryland Baltimore, Baltimore, Maryland 21201, United States.ORCID 0000-0003-3963-3561
Asuka A OrrSchool of Pharmacy, University of Maryland Baltimore, Baltimore, Maryland 21201, United States.ORCID 0000-0003-4628-526X
Mohammad M SajadiInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
Anthony L DeVicoInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
Daniel J DeredgeSchool of Pharmacy, University of Maryland Baltimore, Baltimore, Maryland 21201, United States.ORCID 0000-0002-6897-6523
Alexander D MacKerellSchool of Pharmacy, University of Maryland Baltimore, Baltimore, Maryland 21201, United States.ORCID 0000-0001-8287-6804
Stephen W HoagSchool of Pharmacy, University of Maryland Baltimore, Baltimore, Maryland 21201, United States.ORCID 0000-0003-0657-6951

Funding

Novel bNAB-based treatment and prevention of HIV-1R01AI155150 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SAJADI, MOHAMMAD MOHSENI · 2021 to 2024
$2.8M
Computational Methods for Optimizing Biologics FormulationR43GM130198 · NIGMS · SILCSBIO, LLC · PI JO, SUNHWAN, MACKERELL, ALEXANDER D · 2019 to 2019
$225k
Bill and Melinda Gates Foundation # INV-050487NIAID NIH HHS R01 AI155150NIGMS NIH HHS R43 GM130198
6 · The paper itself

Abstract

N49P9.6-FR-LS and PGT121 are promising antibodies with significant therapeutic potential against HIV infection, but they are prone to precipitation at concentrations greater than 12 to 13 mg/mL. This study evaluates the influence of six excipients─arginine, alanine, sucrose, trehalose, methionine, and glutamate─on the biophysical stability of antibodies. We employed a comprehensive approach, combining computational mAb-excipient interaction analysis via the site-identification by ligand competitive saturation (SILCS) method with extensive experimental characterization. Our experimental matrix included viscosity measurements across temperature gradients, particle size distribution, zeta potential, pH value, and solution appearance, alongside a short-term stability product study at 30 °C and 65% relative humidity, with assessments at t

Indexed as

Antibodies, MonoclonalExcipientsArginineDrug StabilityHumansParticle SizeProtein StabilitySucroseTrehaloseViscosityAntibodies, MonoclonalArginineExcipientsSucroseTrehaloseAntibody stabilityExcipient-protein interactionHigh-concentration protein formulationProtein aggregationSILCS-Biologics

Identifiers

PMID40029670
PMCPMC11975482

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.